Bone Biologics Corp (BBLG, BBLGW (BBLGW) Stock Price, Financials & Summary

Price chart

Sep 11Sep 16Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12

Key dataOct 12, 2026

Open$7.70

From 52W high−78.58%

Volume1.00

Market cap$9.05M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 12, 2026

Open

$7.70

From 52W high

−78.58%

Volume

1.00

Market cap

$9.05M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.0x

P/E (TTM)

—

RSI (14)

64.0

MomentumView details →

1D Return

+0.00%

YTD Return

−50.32%

SummaryUpdated Sep 1, 2026

Bone Biologics Corporation (NASDAQ:BBLG) is a clinical-stage medical device company founded in 2004 and headquartered in Burlington, Massachusetts. The company went public in October 2021 and focuses on developing innovative bone regeneration solutions for spinal fusion procedures. Bone Biologics operates as a pre-revenue biotechnology company, dedicating its efforts to advancing a proprietary recombinant protein technology that aims to enhance bone healing outcomes in orthopedic surgery.

Ask drillr about Bone Biologics Corp (BBLG, BBLGW →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−47.75%

ROA (TTM)

−44.18%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+33.60%

FCF YoY

+22.83%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+45.13%

EBITDA YoY

+10.76%

MomentumView details →

1D Return

+0.00%

YTD Return

−50.32%

1Y Return

−25.89%

RSI (14)

64.0

vs 50D SMA

+25.14%

vs 200D SMA

−50.32%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

13.38x

Quick Ratio

13.38x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.43

EPS Surprise

0.00%

Beats (12Q)

0/12

Next Q EPS Est

−$0.18

Avg Surprise (4Q)

−0.10%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−2.84M

Op. CF (TTM)

−2.57M

Next earningsDec 2, 2026 →

Latest newsMore news →

Bone Biologics Corporation announced that six hospital sites in Australia have agreed to participate in its first-in-human pilot clinical trial of NB1, its rhNELL-1-based bone graft product for spinal fusion.52d ago

Similar companies

Aethlon Medical, Inc.AEMD NeuroOne Medical Technologies CorporationNMTC Biomerica, Inc.BMRA Pulsenmore Ltd. Ordinary SharesPLSM IRIDEX CorporationIRIX Sintx Technologies, Inc.SINT Find similar companies →

Latest newsMore news →

Bone Biologics Corp received a NASDAQ notice dated September 10, 2026 that it no longer complies with the minimum bid price requirement under Listing Rule 5550(a)(2), and intends to seek stockholder approval for a reverse stock split at its upcoming annual meeting.43d ago Bone Biologics Corporation announced that six hospital sites in Australia have agreed to participate in its first-in-human pilot clinical trial of NB1, its rhNELL-1-based bone graft product for spinal fusion.52d ago